Preclinical and translational data indicate FXR activation may restrain, whereas TGR5 activation may promote, CCA progression, highlighting receptor-specific and context-dependent effects of the biliary milieu (24, 25). The gene discussed is NR1H4; the disease is cholangiocarcinoma.